Related references
Note: Only part of the references are listed.Therapeutic Approaches for Women Predisposed to Breast Cancer
Katherine L. Nathanson et al.
ANNUAL REVIEW OF MEDICINE, VOL 62, 2011 (2011)
Relative contributions of BRCA1 and BRCA2 mutations to triple-negative breast cancer in Ashkenazi Women
E. Comen et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
Ana M. Gonzalez-Angulo et al.
CLINICAL CANCER RESEARCH (2011)
Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer
D. G. Evans et al.
JOURNAL OF MEDICAL GENETICS (2011)
Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany
Dorothea Gadzicki et al.
JOURNAL OF COMMUNITY GENETICS (2011)
Expanding the Criteria for BRCA Mutation Testing in Breast Cancer Survivors
Janice S. Kwon et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Triple-Negative Breast Cancer
William D. Foulkes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows et al.
PLOS MEDICINE (2010)
Incorporating tumour pathology information into breast cancer risk prediction algorithms
Nasim Mavaddat et al.
BREAST CANCER RESEARCH (2010)
Relationship Between Clinical and Pathologic Features of Ductal Carcinoma In Situ and Patient Age An Analysis of 657 Patients
Laura C. Collins et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
The prevalence of BRCA1 mutations among young women with triple-negative breast cancer
S. R. Young et al.
BMC CANCER (2009)
Addition of pathology and biomarker information significantly improves the performance of the Manchester scoring system for BRCA1 and BRCA2 testing
D. G. R. Evans et al.
JOURNAL OF MEDICAL GENETICS (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials
L. S. Kilburn
CLINICAL ONCOLOGY (2008)
Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer
Deann P. Atchley et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation:: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics
A. C. Antoniou et al.
JOURNAL OF MEDICAL GENETICS (2008)
Prospective study of outcomes in sporadic versus hereditary breast cancer (POSH): study protocol
Diana Eccles et al.
BMC CANCER (2007)
Descriptive analysis of estrogen receptor (ER)negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype - A population-based study from the California Cancer Registry
Katrina R. Bauer et al.
CANCER (2007)
Update on the Manchester scoring system for BRCA1 and BRCA2 testing -: art. no. e39
DGR Evans et al.
JOURNAL OF MEDICAL GENETICS (2005)
American Society of Clinical Oncology policy statement update: Genetic testing for cancer susceptibility
SS Bruinooge
JOURNAL OF CLINICAL ONCOLOGY (2003)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
Share Paper
